JP2014516515A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516515A5 JP2014516515A5 JP2014506699A JP2014506699A JP2014516515A5 JP 2014516515 A5 JP2014516515 A5 JP 2014516515A5 JP 2014506699 A JP2014506699 A JP 2014506699A JP 2014506699 A JP2014506699 A JP 2014506699A JP 2014516515 A5 JP2014516515 A5 JP 2014516515A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- elution buffer
- buffered saline
- phosphate buffered
- gel permeation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 46
- 239000012149 elution buffer Substances 0.000 claims description 33
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 25
- 239000002953 phosphate buffered saline Substances 0.000 claims description 25
- 238000005227 gel permeation chromatography Methods 0.000 claims description 24
- 238000011084 recovery Methods 0.000 claims description 19
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 18
- 241000702263 Reovirus sp. Species 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 12
- 229930006000 Sucrose Natural products 0.000 claims description 12
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 12
- 239000005720 sucrose Substances 0.000 claims description 12
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 10
- 150000001768 cations Chemical class 0.000 claims description 10
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 10
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 10
- 229920000053 polysorbate 80 Polymers 0.000 claims description 10
- 229940068968 polysorbate 80 Drugs 0.000 claims description 10
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 6
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 6
- 235000019800 disodium phosphate Nutrition 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 6
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 6
- 239000002736 nonionic surfactant Substances 0.000 claims description 6
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 235000002639 sodium chloride Nutrition 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- 235000010356 sorbitol Nutrition 0.000 claims description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 150000003841 chloride salts Chemical class 0.000 claims description 5
- 235000021317 phosphate Nutrition 0.000 claims description 5
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 5
- 239000001103 potassium chloride Substances 0.000 claims description 5
- 235000011164 potassium chloride Nutrition 0.000 claims description 5
- 239000001488 sodium phosphate Substances 0.000 claims description 5
- 230000000717 retained effect Effects 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 2
- 235000014304 histidine Nutrition 0.000 claims description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 2
- 244000309711 non-enveloped viruses Species 0.000 claims description 2
- 244000309459 oncolytic virus Species 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161480561P | 2011-04-29 | 2011-04-29 | |
| US61/480,561 | 2011-04-29 | ||
| PCT/CA2012/000406 WO2012145837A1 (en) | 2011-04-29 | 2012-04-27 | Methods of purifying viruses using gel permeation chromatography |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014516515A JP2014516515A (ja) | 2014-07-17 |
| JP2014516515A5 true JP2014516515A5 (cg-RX-API-DMAC10.html) | 2015-06-18 |
| JP6029651B2 JP6029651B2 (ja) | 2016-11-24 |
Family
ID=47067091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506699A Active JP6029651B2 (ja) | 2011-04-29 | 2012-04-27 | ゲル浸透クロマトグラフィーを使用してウイルスを精製する方法 |
Country Status (15)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2819236A1 (en) | 2010-12-02 | 2012-06-07 | Oncolytics Biotech Inc. | Lyophilized viral formulations |
| MX373096B (es) * | 2010-12-02 | 2020-04-27 | Oncolytics Biotech Inc | Formulaciones virales líquidas. |
| RS57864B1 (sr) * | 2013-06-17 | 2018-12-31 | De Staat Der Nederlanden Vert Door De Minister Van Vws Ministerie Van Volksgezondheid Welzijn En Spo | Postupci za sprečavanje agregacije virusnih komponenti |
| CA3104392A1 (en) | 2018-07-04 | 2020-01-09 | Probiogen Ag | Method for purifying an enveloped virus |
| CN111812313B (zh) * | 2020-06-22 | 2021-10-08 | 北京生物制品研究所有限责任公司 | 铝佐剂吸附型新型冠状病毒灭活疫苗中抗原的解离方法 |
| CN114544815B (zh) * | 2022-03-01 | 2023-10-27 | 中牧实业股份有限公司 | 一种山羊痘病毒的定量检测方法 |
| CN116718524B (zh) * | 2023-06-26 | 2025-11-07 | 西安交通大学 | 一种基于细胞膜色谱技术的病毒颗粒检测方法 |
| HUP2400154A1 (hu) * | 2024-02-29 | 2025-09-28 | Pecsi Tudomanyegyetem | Elúciós oldat és tisztítási eljárás |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
| DE69029765T2 (de) * | 1989-07-24 | 1997-05-15 | Bayer Ag | Stabilisierung von hochgereinigten Proteinen |
| ES2264126T3 (es) * | 1994-05-16 | 2006-12-16 | MERCK & CO., INC. | Vacunas contra el papilomavirus. |
| KR100918187B1 (ko) * | 1998-02-17 | 2009-09-22 | 쉐링 코포레이션 | 바이러스를 포함하는 조성물 및 바이러스 제제의 농축방법 |
| IL157304A0 (en) | 2001-03-16 | 2004-02-19 | Oncolytics Biotech Inc | Method of extracting virus from cell culture |
| DE60327069D1 (de) * | 2002-04-30 | 2009-05-20 | Oncolytics Biotech Inc | Verbesserte reinigungsmethode für viren |
| US7901921B2 (en) * | 2004-10-22 | 2011-03-08 | Oncolytics Biotech Inc. | Viral purification methods |
| EP1878791A1 (en) * | 2006-07-11 | 2008-01-16 | Bia Separations D.O.O. | Method for influenza virus purification |
| CA2662569C (en) * | 2006-08-07 | 2017-01-03 | Japan As Represented By Director General Of National Institute Of Infectious Diseases | Process for preparing live smallpox vaccine |
| SG191602A1 (en) * | 2007-03-12 | 2013-07-31 | Oncolytics Biotech Inc | Reoviruses having modified sequences |
| AU2008321016B2 (en) * | 2007-11-12 | 2013-03-28 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
| US8227577B2 (en) * | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| CA2819236A1 (en) * | 2010-12-02 | 2012-06-07 | Oncolytics Biotech Inc. | Lyophilized viral formulations |
| MX373096B (es) * | 2010-12-02 | 2020-04-27 | Oncolytics Biotech Inc | Formulaciones virales líquidas. |
-
2012
- 2012-04-27 EA EA201391605A patent/EA201391605A1/ru unknown
- 2012-04-27 CA CA2832367A patent/CA2832367A1/en not_active Abandoned
- 2012-04-27 MX MX2013012627A patent/MX337348B/es active IP Right Grant
- 2012-04-27 DK DK12776970.1T patent/DK2702147T3/da active
- 2012-04-27 WO PCT/CA2012/000406 patent/WO2012145837A1/en not_active Ceased
- 2012-04-27 ES ES12776970T patent/ES2822199T3/es active Active
- 2012-04-27 EP EP12776970.1A patent/EP2702147B1/en active Active
- 2012-04-27 KR KR1020137031292A patent/KR20140024406A/ko not_active Ceased
- 2012-04-27 AU AU2012248082A patent/AU2012248082B2/en active Active
- 2012-04-27 TW TW101115116A patent/TW201307561A/zh unknown
- 2012-04-27 SG SG2013075569A patent/SG194449A1/en unknown
- 2012-04-27 KR KR1020197006419A patent/KR102151890B1/ko active Active
- 2012-04-27 CN CN201280020376.8A patent/CN103492557B/zh active Active
- 2012-04-27 JP JP2014506699A patent/JP6029651B2/ja active Active
- 2012-04-27 US US13/457,642 patent/US20120273424A1/en not_active Abandoned
-
2013
- 2013-09-17 IL IL228491A patent/IL228491A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ferreri et al. | Marginal zone lymphomas and infectious agents | |
| JP2014520852A5 (cg-RX-API-DMAC10.html) | ||
| JP2012126742A5 (cg-RX-API-DMAC10.html) | ||
| CO2017010162A2 (es) | Nucleótidos de purina ß-d-2'-desoxi-2'-α-fluoro-2'-ß-c-sustituidos-2-modificados-n6-sustituidos para el tratamiento del virus de la hepatitis c | |
| JP2015091902A5 (cg-RX-API-DMAC10.html) | ||
| JP2016538885A5 (cg-RX-API-DMAC10.html) | ||
| Manzoni et al. | High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention | |
| JP2012136541A5 (cg-RX-API-DMAC10.html) | ||
| EA202090465A1 (ru) | Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк- и/или днк-содержащими вирусами, и сопутствующих заболеваний | |
| JP2014051497A5 (cg-RX-API-DMAC10.html) | ||
| JP2015524421A5 (cg-RX-API-DMAC10.html) | ||
| JP2015521206A5 (cg-RX-API-DMAC10.html) | ||
| JP2017526689A5 (cg-RX-API-DMAC10.html) | ||
| WO2012075379A3 (en) | Liquid viral formulations | |
| MX349294B (es) | Formulaciones virales liofilizadas. | |
| SG194449A1 (en) | Methods of purifying viruses using gel permeation chromatography | |
| JP2016528176A5 (cg-RX-API-DMAC10.html) | ||
| JP2016518321A5 (cg-RX-API-DMAC10.html) | ||
| JP2016505009A5 (cg-RX-API-DMAC10.html) | ||
| JP2018522894A5 (cg-RX-API-DMAC10.html) | ||
| Carbone-Schellman et al. | Therapeutic challenges in central nervous system viral infections: advancing mesenchymal stem cell-based strategies for treating neuroinflammation and promoting tissue repair | |
| Islam et al. | An in‐depth analysis of COVID‐19 treatment: Present situation and prospects | |
| Zhang et al. | Innovation-driven trend shaping COVID-19 vaccine development in China | |
| Gordien | The hepatitis delta virus infection: recent data in France | |
| Chung et al. | Current Progress in Dengue Vaccine Clinical Trial |